{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:15:31Z","timestamp":1790252131893,"version":"4.1.0"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2017,4,19]],"date-time":"2017-04-19T00:00:00Z","timestamp":1492560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Kaposi sarcoma inflammatory cytokine syndrome (KICS) is a newly-described condition affecting individuals who are HIV-positive and are infected with human herpesvirus 8 (HHV-8). This is a syndrome that in some ways mimics severe sepsis with associated acute respiratory distress syndrome, possibly requiring a ventilator and vasopressor support. However, unlike severe sepsis, antibiotics provide no benefit. Management of KICS has not been fully elucidated because of its high mortality rate. However, the syndrome has been successfully treated in some cases with immunomodulatory therapy. It is crucial for oncologists to be able to recognize this syndrome and to institute the appropriate therapy.<\/jats:p>","DOI":"10.1634\/theoncologist.2016-0237","type":"journal-article","created":{"date-parts":[[2017,4,20]],"date-time":"2017-04-20T00:50:31Z","timestamp":1492649431000},"page":"623-625","source":"Crossref","is-referenced-by-count":37,"title":["Kaposi Sarcoma Inflammatory Cytokine Syndrome (KICS): A Rare but Potentially Treatable Condition"],"prefix":"10.1093","volume":"22","author":[{"given":"Michael","family":"Karass","sequence":"first","affiliation":[{"name":"New York Medical College, Valhalla, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Grossniklaus","sequence":"additional","affiliation":[{"name":"Emory University, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talal","family":"Seoud","sequence":"additional","affiliation":[{"name":"American University of Beirut, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Jain","sequence":"additional","affiliation":[{"name":"Morehouse School of Medicine Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Goldstein","sequence":"additional","affiliation":[{"name":"Emory University, Atlanta, Georgia, USA"},{"name":"Rabin Medical Center, Petach Tikvah, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,4,19]]},"reference":[{"key":"2021122508014677000_onco12101-bib-0001","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1182\/blood-2014-07-586800","article-title":"Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease","volume":"124","author":"Uldrick","year":"2014","journal-title":"Blood"},{"key":"2021122508014677000_onco12101-bib-0002","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1086\/654798","article-title":"Interleukin-6-related systemic inflammatory syndrome in patients coinfected with Kaposi sarcoma-associated herpesvirus and HIV but without multicentric Castleman disease","volume":"51","author":"Uldrick","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2021122508014677000_onco12101-bib-0003","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1093\/cid\/civ996","article-title":"Clinical features and outcomes of patients with symptomatic Kaposi sarcoma herpesvirus (KSHV)-associated Inflammation: (KICS)","volume":"62","author":"Polizzotto","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2021122508014677000_onco12101-bib-0004","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1172\/JCI114749","article-title":"Dysregulated interleukin-6 expression produces a syndrome resembling Castleman's syndrome","volume":"86","author":"Brandt","year":"1990","journal-title":"J Clin Invest"},{"key":"2021122508014677000_onco12101-bib-0005","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3389\/fmicb.2012.00073","article-title":"Clinical manifestations of Kaposi sarcoma herpes virus lytic activation: Multicentric Castleman disease (KSHV\u2013MCD) and the KSHV inflammatory cytokine syndrome","volume":"3","author":"Polizzotto","year":"2012","journal-title":"Front Microbiol"},{"key":"2021122508014677000_onco12101-bib-0006","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1053\/j.seminoncol.2014.12.027","article-title":"Kaposi sarcoma\u2013associated herpesvirus-associated malignancies: Epidemiology, pathogenesis, and advances in treatment","volume":"42","author":"Bhutani","year":"2015","journal-title":"Semin Oncol"},{"key":"2021122508014677000_onco12101-bib-0007","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1086\/595006","article-title":"HIV\/AIDS: Immune reconstitution inflammatory syndrome: A reappraisal","volume":"48","author":"French","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2021122508014677000_onco12101-bib-0008","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1086\/499356","article-title":"Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort","volume":"42","author":"Ratnam","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2021122508014677000_onco12101-bib-0009","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/QAI.0b013e3181594c8c","article-title":"Immune reconstitution inflammatory syndrome: Risk factors and treatment implications","volume":"46","author":"Manabe","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2021122508014677000_onco12101-bib-0010","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0002-9394(01)01322-8","article-title":"Characteristics of patients with cytomegalovirus retinitis in the era of highly active antiretroviral therapy","volume":"133","author":"Jabs","year":"2002","journal-title":"Am J Ophthalmol"},{"key":"2021122508014677000_onco12101-bib-0011","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1086\/425742","article-title":"Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy","volume":"39","author":"Breton","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2021122508014677000_onco12101-bib-0012","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1634\/theoncologist.12-5-569","article-title":"Primary effusion lymphoma","volume":"12","author":"Chen","year":"2007","journal-title":"The Oncologist"},{"key":"2021122508014677000_onco12101-bib-0013","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1182\/blood.V86.4.1276.bloodjournal8641276","article-title":"Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease","volume":"86","author":"Soulier","year":"1995","journal-title":"Blood"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2016-0237","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2016-0237","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/22\/5\/623\/41916153\/oncolo_22_5_623.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/22\/5\/623\/41916153\/oncolo_22_5_623.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T08:02:09Z","timestamp":1640419329000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/22\/5\/623\/6438916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,19]]},"references-count":13,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2017,4,19]]},"published-print":{"date-parts":[[2017,5,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2016-0237","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,5,1]]},"published":{"date-parts":[[2017,4,19]]}}}